Jacob Chacko compensation by year
Oric Pharmaceuticals Summary Compensation Table · all 8 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Salary | $290,000 | $455,833 | $489,167 | $536,278 | $572,103 | $596,083 | $627,333 | $657,500 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $474,000 | $396,000 | $776,900 | $826,000 |
| Option awards | $1,194,442 | $0 | $5,082,831 | $6,092,240 | $2,970,009 | $1,796,080 | $3,466,878 | $3,634,560 |
| Non-equity incentive | $92,800 | $194,900 | $300,800 | $335,200 | $336,110 | $350,200 | $396,800 | $434,000 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $57,897 | $21,396 | $988 | $12,206 | $13,108 | $14,720 | $14,904 | $15,104 |
| Total | $1,635,139 | $672,129 | $5,873,786 | $6,975,924 | $4,365,330 | $3,153,083 | $5,282,815 | $5,567,164 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Oric Pharmaceuticals, Inc. DEF 14A filed April 28, 2026, accession 0001193125-26-186911, and prior-year filings.
How this page was built: the Oric Pharmaceuticals, Inc. filed document, accession 0001193125-26-186911. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 66,667 | $545,336 | — |
| RSU | 28,334 | $231,772 | — |
| Option | 116,667 | — | $6.00 |
| Option | 600,000 | — | $8.26 |
| Option | 84,584 | — | $4.36 |
| Option | 265,625 | — | $9.14 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Oric Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Oric Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jacob Chacko · this page | President, Chief Executive Officer and Director | $5,567,164 |
| Pratik Multani | Chief Medical Officer | $2,282,441 |
| Dominic Piscitelli | Chief Financial Officer | $2,237,425 |
Board service
Oric Pharmaceuticals board · FY2021–FY2025How this board is paid
Company policy: Oric Pharmaceuticals pays directors a $40,000 cash retainer. As stated in Oric Pharmaceuticals's FY2025 proxy.
The full Oric Pharmaceuticals compensation record
free company briefThis page is one person within Oric Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Oric Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Oric Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.